Skip to main content
. Author manuscript; available in PMC: 2016 May 17.
Published in final edited form as: Pain. 2013 Jul 25;154(11):2432–2440. doi: 10.1016/j.pain.2013.07.032

Fig. 1.

Fig. 1

Mn(III) 5,10,15,20-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin (MnTE-2-PyP5+) blocks oxaliplatin (Ox)-induced neuropathic pain in a dose-dependent manner. When compared with baseline [day (D)0], treatment with oxaliplatin (●), but not with its vehicle (Veh) (○), led to the time-dependent development of mechano-allodynia (A) and mechano-hyperalgesia (B). Daily (D0–17) injections of MnTE-2-PYP5+ (0.3 mg/kg/d, ▲; 1 mg/kg/d, ▼; 3 mg/kg/d, ■) significantly attenuated the development of oxaliplatin-induced mechano-hypersensitivity in a dose-dependent manner (A, B). Results are expressed as mean ± SD, n = 5–7 and analyzed by two-way analysis of variance with Bonferroni’s post-hoc comparisons. *P < .001 (tday vs tday 0); †P < .001 (Ox + MnTE-2-PyP5+ vs Ox). PWT = paw withdrawal threshold.